BLRX - BioLineRx Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

BioLineRx Ltd.

Modi'in Technology Park
2 HaMa'ayan Street
Modi'in 7177871
Israel
972 8 642 9100
http://www.biolinerx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees51

Key Executives

NameTitlePayExercisedYear Born
Mr. Philip A. SerlinChief Exec. Officer489kN/A1960
Ms. Mali ZeeviCFO & Principal Accounting OfficerN/AN/A1976
Dr. Ella SoraniVP R&D280kN/A1968
Dr. Abi Vainstein-Haras M.D.VP of Clinical and Medical Affairs302kN/A1975
Advocate Norman KotlerInternal Enforcement Officer, Gen. Counsel and Corp. Sec.N/AN/A1952
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions. The company's other therapeutic candidates comprise BL-1040, a resorbable polymer solution for use in the prevention of ventricular remodeling; BL-9020, which is a monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; and BL-1230, a cannabinoid receptor type 2 intended as an anti-inflammatory treatment for dry eye syndrome. The company has collaboration agreement with Novartis Pharma AG to facilitate development and commercialization of Israeli-sourced drug candidates; MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 and Genentech's Atezolizumab in various Phase 1b/2 studies for in various solid tumors and hematologic malignancies. BioLineRx Ltd. was founded in 2003 and is headquartered in Modi'in, Israel.

Corporate Governance

BioLineRx Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.